Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma

IMPORTANCE: Administration of atezolizumab could be immunogenic and induce undesirable antidrug antibody (ADA) responses. This may interfere with atezolizumab-mediated actions, affecting drug clearance and serum concentration or inducing antibody neutralization. OBJECTIVE: To determine the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Chan, Yang, Hannah, Kim, Ilhwan, Kang, Beodeul, Kim, Hyeyeong, Kim, Hyunho, Lee, Won Suk, Jung, Sanghoon, Lim, Ho Yeong, Cheon, Jaekyung, Chon, Hong Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585463/
https://www.ncbi.nlm.nih.gov/pubmed/36264560
http://dx.doi.org/10.1001/jamaoncol.2022.4733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585463/
https://www.ncbi.nlm.nih.gov/pubmed/36264560
http://dx.doi.org/10.1001/jamaoncol.2022.4733

Ejemplares similares